drugset / Trial / NCT03794310

Study of NPF-08 in Patients Who Receive Colonoscopy

NCT03794310

Phase 3 Completed 632 enrolled Nihon Pharmaceutical Co., Ltd
RandomizedParallel-groupSingle-blindDiagnostic

Summary

To study non-inferiority of intestinal cleansing effect in both NPF-08 1-day treatment group and NPF-08 2-day split dose group to the cleansing effect in Moviprep® 1-day treatment group, for the subjects who will receive endoscopy large bowel. If the non-inferiority will be validated, superiority of intestinal cleansing effect in both groups of NPF-08 will be studied. Furthermore, for the assessment of safety of NPF-08, the adverse events and adverse drug reactions observed after the administration to post-examination period will be studied, compared to those at Moviprep® 1-day treatment group.

Timeline

Start
2019-01-05
Primary completion
2019-06-19
Completion
2019-06-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moviprep Other / unclassified
Subject NPF-08 Unknown Oral

Indications

No indication recorded.